{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:45Z","timestamp":1787988045284,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473381"],"award-info":[{"award-number":["82473381"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172621"],"award-info":[{"award-number":["82172621"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Medical Innovation Research Special Project","award":["21Y11904300"],"award-info":[{"award-number":["21Y11904300"]}]},{"name":"Shanghai Academic\/Technology Research Leader","award":["23XD1420600"],"award-info":[{"award-number":["23XD1420600"]}]},{"name":"Shanghai Shenkang Research Physician Innovation and Transformation Ability Training Project","award":["SHDC2022CRD035"],"award-info":[{"award-number":["SHDC2022CRD035"]}]},{"name":"Clinical Research Plan of SHDC","award":["SHDC-2020CR2016B"],"award-info":[{"award-number":["SHDC-2020CR2016B"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["BX20250228"],"award-info":[{"award-number":["BX20250228"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"China Urological Oncology Research Foundation"},{"name":"Oriental Scholar Professorship"},{"name":"Clinical Research Project of Shanghai Municipal Health Bureau","award":["20234Y0118"],"award-info":[{"award-number":["20234Y0118"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00259-026-07982-4","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T01:47:05Z","timestamp":1780883225000},"page":"6429-6441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial"],"prefix":"10.1007","volume":"53","author":[{"given":"Jian","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7950-6669","authenticated-orcid":false,"given":"Yao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"6","key":"7982_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","volume":"5","author":"D Menges","year":"2022","unstructured":"Menges D, Yebyo HG, Sivec-Muniz S, Haile SR, Barbier MC, Tomonaga Y, et al. Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment. Eur Urol Oncol. 2022;5(6):605\u201316. https:\/\/doi.org\/10.1016\/j.euo.2022.04.007.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"7982_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307.","journal-title":"N Engl J Med"},{"issue":"5","key":"7982_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","volume":"34","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, et al. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol. 2023;34(5):477\u201385. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.009.","journal-title":"Ann Oncol"},{"issue":"1","key":"7982_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7982_CR5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","volume":"7","author":"A Ali","year":"2021","unstructured":"Ali A, Hoyle A, Haran AM, Brawley CD, Cook A, Amos C, et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2021;7(4):555\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7857.","journal-title":"JAMA Oncol"},{"issue":"1","key":"7982_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5977-6","volume":"19","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19(1):816. https:\/\/doi.org\/10.1186\/s12885-019-5977-6.","journal-title":"BMC Cancer"},{"key":"7982_CR7","doi-asserted-by":"publisher","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558\u201365. https:\/\/doi.org\/10.1200\/JCO.19.00201.","DOI":"10.1200\/JCO.19.00201"},{"key":"7982_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.euros.2022.04.003","volume":"40","author":"N Huebner","year":"2022","unstructured":"Huebner N, Rasul S, Baltzer P, Clauser P, Hermann Grubmuller K, Mitterhauser M, et al. Feasibility and optimal time point of [(68)Ga]gallium-labeled prostate-specific membrane antigen ligand positron emission tomography imaging in patients undergoing cytoreductive surgery after systemic therapy for primary oligometastatic prostate cancer: implications for patient selection and extent of surgery. Eur Urol Open Sci. 2022;40:117\u201324. https:\/\/doi.org\/10.1016\/j.euros.2022.04.003.","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"7982_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147.","journal-title":"JAMA Oncol"},{"issue":"1","key":"7982_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/JU.0000000000002492","volume":"208","author":"JR Bright","year":"2022","unstructured":"Bright JR, Lis RT, Ku AT, Terrigino NT, Whitlock NC, Trostel SY, et al. Prostate-specific membrane antigen is a biomarker for residual disease following neoadjuvant intense androgen deprivation therapy in prostate cancer. J Urol. 2022;208(1):90\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000002492.","journal-title":"J Urol"},{"issue":"1","key":"7982_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12395-3","volume":"24","author":"B Wang","year":"2024","unstructured":"Wang B, Pan J, Zhang T, Ni X, Wei Y, Li X, et al. Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy. BMC Cancer. 2024;24(1):643. https:\/\/doi.org\/10.1186\/s12885-024-12395-3.","journal-title":"BMC Cancer"},{"issue":"12","key":"7982_CR12","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"issue":"6","key":"7982_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","volume":"83","author":"G Devos","year":"2023","unstructured":"Devos G, Tosco L, Baldewijns M, Gevaert T, Goffin K, Petit V, et al. ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer. Eur Urol. 2023;83(6):508\u201318. https:\/\/doi.org\/10.1016\/j.eururo.2022.09.009.","journal-title":"Eur Urol"},{"issue":"11","key":"7982_CR14","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080\u20137. https:\/\/doi.org\/10.1200\/JCO.2017.75.3657.","journal-title":"J Clin Oncol"},{"issue":"12","key":"7982_CR15","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.medj.2024.07.020","volume":"5","author":"J Pan","year":"2024","unstructured":"Pan J, Wu J, Wang B, Zhu B, Liu X, Gan H, et al. Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer. Med. 2024;5(12):1475-1484.e3. https:\/\/doi.org\/10.1016\/j.medj.2024.07.020.","journal-title":"Med"},{"issue":"4","key":"7982_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.euo.2022.02.002","volume":"5","author":"J Pan","year":"2022","unstructured":"Pan J, Wei Y, Zhang T, Liu C, Hu X, Zhao J, et al. Stereotactic radiotherapy for lesions detected via (68)Ga-prostate-specific membrane antigen and (18)F-fluorodexyglucose positron emission tomography\/computed tomography in patients with nonmetastatic prostate cancer with early prostate-specific antigen progression on androgen deprivation therapy: a prospective single-center study. Eur Urol Oncol. 2022;5(4):420\u20137. https:\/\/doi.org\/10.1016\/j.euo.2022.02.002.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"7982_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.09.009","volume":"6","author":"X Bian","year":"2025","unstructured":"Bian X, Gu W, Zhang X, Xie L, Wang S, Shi B, et al. Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial. Med. 2025;6(2):100520. https:\/\/doi.org\/10.1016\/j.medj.2024.09.009.","journal-title":"Med"},{"issue":"10","key":"7982_CR18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1470-2045(22)00507-1","volume":"23","author":"W Gu","year":"2022","unstructured":"Gu W, Han W, Luo H, Zhou F, He D, Ma L, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022;23(10):1249\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(22)00507-1.","journal-title":"Lancet Oncol"},{"issue":"4","key":"7982_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","volume":"86","author":"F Saad","year":"2024","unstructured":"Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, et al. Deep and durable prostate-specific antigen response to darolutamide with androgen deprivation therapy and docetaxel, and association with clinical outcomes for patients with high- or low-volume metastatic hormone-sensitive prostate cancer: analyses of the randomized phase 3 ARASENS study. Eur Urol. 2024;86(4):329\u201339. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.036.","journal-title":"Eur Urol"},{"issue":"4","key":"7982_CR20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","volume":"36","author":"LC Harshman","year":"2018","unstructured":"Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, et al. Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel. J Clin Oncol. 2018;36(4):376\u201382. https:\/\/doi.org\/10.1200\/JCO.2017.75.3921.","journal-title":"J Clin Oncol"},{"issue":"10162","key":"7982_CR21","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3.","journal-title":"Lancet"},{"issue":"3","key":"7982_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","volume":"26","author":"G Marvaso","year":"2025","unstructured":"Marvaso G, Corrao G, Zaffaroni M, Vincini MG, Lorubbio C, Gandini S, et al. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol. 2025;26(3):300\u201311. https:\/\/doi.org\/10.1016\/S1470-2045(24)00730-7.","journal-title":"Lancet Oncol"},{"issue":"3","key":"7982_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.euo.2023.12.007","volume":"7","author":"C Corsini","year":"2024","unstructured":"Corsini C, Bergengren O, Carlsson S, Garmo H, Hjelm-Eriksson M, Fransson P, et al. Patient-reported side effects 1 year after radical prostatectomy or radiotherapy for prostate cancer: a register-based nationwide study. Eur Urol Oncol. 2024;7(3):605\u201313. https:\/\/doi.org\/10.1016\/j.euo.2023.12.007.","journal-title":"Eur Urol Oncol"},{"issue":"5_suppl","key":"7982_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/JCO.2025.43.5_suppl.160","volume":"43","author":"G Francolini","year":"2025","unstructured":"Francolini G, Di Cataldo V, Garlatti P, Caini S, Bruni A, Simoni N, et al. PERSIAN trial: early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer. J Clin Oncol. 2025;43(5_suppl):160\u2013160. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.160.","journal-title":"J Clin Oncol"},{"issue":"35","key":"7982_CR25","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol. 2023;41(35):5561\u20138. https:\/\/doi.org\/10.1200\/JCO.23.00985.","journal-title":"J Clin Oncol"},{"issue":"7","key":"7982_CR26","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2967\/jnumed.125.269913","volume":"66","author":"S Satapathy","year":"2025","unstructured":"Satapathy S, Das CK, Goyal S, Sood A, Periasamy K, Aggarwal P, et al. (177)Lu-PSMA-617 consolidation therapy after docetaxel in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer: a randomized, phase 2 trial. J Nucl Med. 2025;66(7):1068\u201374. https:\/\/doi.org\/10.2967\/jnumed.125.269913.","journal-title":"J Nucl Med"},{"issue":"5","key":"7982_CR27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ijrobp.2022.05.035","volume":"114","author":"S Ashram","year":"2022","unstructured":"Ashram S, Bahig H, Barry A, Blanchette D, Celinksi A, Chung P, et al. Planning trade-offs for SABR in patients with 4 to 10 metastases: a substudy of the SABR-COMET-10 randomized trial. Int J Radiat Oncol Biol Phys. 2022;114(5):1011\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.035.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10231","key":"7982_CR28","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"issue":"1","key":"7982_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2967\/jnumed.124.268441","volume":"66","author":"LM Unterrainer","year":"2025","unstructured":"Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, et al. Low- and high-volume disease in metastatic hormone-sensitive prostate cancer: from CHAARTED to PSMA PET-an international multicenter retrospective study. J Nucl Med. 2025;66(1):54\u201360. https:\/\/doi.org\/10.2967\/jnumed.124.268441.","journal-title":"J Nucl Med"},{"issue":"12","key":"7982_CR30","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00259-018-4079-z","volume":"45","author":"A Afshar-Oromieh","year":"2018","unstructured":"Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET\/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(12):2045\u201354. https:\/\/doi.org\/10.1007\/s00259-018-4079-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7982_CR31","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000001481","volume":"205","author":"M Chen","year":"2021","unstructured":"Chen M, Zhuang J, Fu Y, Guo S, Zang S, Ai S, et al. Can (68)Ga-PSMA-11 positron emission tomography\/computerized tomography predict pathological response of primary prostate cancer to neoadjuvant androgen deprivation therapy? A pilot study. J Urol. 2021;205(4):1082\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000001481.","journal-title":"J Urol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07982-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07982-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07982-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:29Z","timestamp":1787986829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07982-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7982"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07982-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Financial disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study involving human participants was in line with the principles of the ethics committee of Fudan University Shanghai Cancer Center and the Declaration of Helsinki in 1964. This study does not include animal research.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}